Breaking away from traditional PDE5 inhibitors, PT-141 is the first intelligent peptide capable of reshaping neural circuits related to sexual motivation. Its core innovation lies in targeting the melanin receptor MC4R in the brain, not directly acting on peripheral blood vessels, but reprogramming sexual reward memories in the ventromedial hypothalamus, eliminating "sexual deprivation circuits" caused by factors such as anxiety, depression, and medication. By rebuilding the spatiotemporal dialogue between the dopamine and melanin systems, it restores the instinctive drive of desire from its neural origins.
|
Name |
PT-141 |
|
Appearance |
White freeze-dried powder |
|
Purity |
99%+ |
|
Minimum order |
10vials/kit |
|
Estate/Nation |
Shenzhen, China |
|
Accepted payment methods |
BTC/USDT/Bank Transfer/Western Union |
|
Transportation time |
Around 10-15days |
Content:

PT-141 (Bremerlongan) is not a traditional vasodilator, but rather a "neural key" that precisely unlocks the brain's desire center. As a cyclic synthetic heptapeptide, it is a metabolic analog of α-melanocyte-stimulating hormone (α-MSH), but its design cleverly avoids the side effect of affecting skin pigmentation, instead focusing on activating melanocortin-4 receptors (MC4R) in the central nervous system. It does not act directly on blood vessels or sexual organs, but fundamentally awakens suppressed libido by modulating neural signals in brain regions such as the hypothalamus, providing a unique and powerful molecular tool for exploring the neurobiological mechanisms of sexual dysfunction.
Advantages: A Precise "Igniter" Targeting the Central Nervous System
PT-141's core advantage lies in the "upstream" and "precise" nature of its mechanism of action. Unlike PDE5 inhibitors such as sildenafil, which act like clearing downstream "rivers," PT-141 directly ignites the "fire of desire" in the brain.
Centrally Driven, Source Activation: It directly stimulates neural pathways associated with sexual arousal by activating MC4R receptors, promoting the release of neurotransmitters such as dopamine and norepinephrine. This makes it particularly effective for sexual dysfunction caused by psychological or neurological factors (such as decreased libido caused by SSRIs), as it bypasses damaged peripheral vascular pathways and addresses the problem directly at its source.
Universally Applicable to Both Men and Women: Its target site is located in the brain, a mechanism shared by both men and women. Therefore, PT-141 is one of the few compounds that can simultaneously provide solutions for erectile dysfunction (ED) in men and hypoactive sexual desire disorder (HSDD) in women, demonstrating its broad physiological regulatory potential.
No Cardiovascular Dilatation Risk: Because it does not act on vascular smooth muscle, PT-141 avoids the cardiovascular side effects such as decreased blood pressure common with PDE5 inhibitors, providing a safer exploration path for research subjects with mild cardiovascular concerns.
Precautions: The Double-Edged Sword Effect of Neural Regulation
However, as a "key" to directly intervene in the nervous system, the use of PT-141 comes with significant precautions.
Significant Side Effects: The most common side effect is nausea (occurring in 30%-40% of cases), which results from the activation of MC4R receptors directly affecting the hypothalamic appetite center. Facial flushing, headache, and injection site reactions are also common. These reactions are a direct manifestation of its potent physiological activity.
Strict Dosing Window: Its short half-life means it typically takes effect 45 minutes to 1 hour before sexual activity via subcutaneous injection. This "on-demand" dosing pattern requires precise timing management, and it cannot be repeated within 24 hours, limiting its flexibility.
Contraindications and Potential Risks: Individuals with uncontrolled hypertension, a history of cardiovascular disease, or mental illness (such as mania) should absolutely avoid use. It may cause transient increases in blood pressure and mood swings, posing a potential risk to individuals with pre-existing conditions.
Uncertainties in the research phase: Although it has been approved by the FDA for specific indications, as an investigational compound, its long-term safety, dependence, and interactions with other neuroactive substances still require further investigation.
Hot Tags: premium pt141, China premium pt141 manufacturers, suppliers











